Statement: the most recurrent adverse occurrence noted in the primary clinical trial was syncope
Primary_evidence: Adverse Events 1:   Total: 5/55 (9.09%)   Infection 2/55 (3.64%)   Pain * 1/55 (1.82%)   Muscle Weakness * 1/55 (1.82%)   Dyspnea 1/55 (1.82%)